Editorial policy
This page describes how articles on Retatrutide Risk are researched, written, checked and corrected.
1. Sources we accept
- Peer-reviewed publications with a DOI registered at CrossRef. The retatrutide evidence base currently rests on the phase 1 and phase 2 papers in Cell Metabolism, The Lancet, the New England Journal of Medicine and Nature Medicine.
- ClinicalTrials.gov registrations, read through the official API, for trial design, doses, enrollment and completion dates.
- FDA prescribing information for approved compounds of the same class (for example tirzepatide), used only for class-level warnings and clearly labelled as such.
- Dated company announcements from Eli Lilly for phase 3 topline results that have not yet been published in a journal. These are labelled “company announcement, not peer-reviewed”.
2. Sources we do not accept
Forum posts, social media, vendor pages, influencer content and secondary blogs are not used as sources of figures. They may be described as what people report, but a number that only exists on a forum is not presented as a fact.
3. Verification
Before a DOI is published it is resolved through the CrossRef API and the returned title, journal and authors are compared with the citation. Before a trial identifier is published it is resolved through the ClinicalTrials.gov API. Figures quoted from abstracts are copied, not rounded or recomputed, and the unit and time point are kept.
4. What we do not write
- Personal dosing recommendations, cycles or protocols.
- Claims that retatrutide is approved, safe or effective for anyone.
- Reviews, testimonials or ratings of any product or vendor.
5. Commercial separation
The bar at the top of every page links to a research-use supplier. That link is the only commercial element of the site. It does not influence which studies are cited or how findings are described, and no article contains sponsored content. The site carries no advertising, affiliate widgets, analytics or cookies.
6. Updates and corrections
Each article displays a publication date and, when changed, an update date. Substantive changes (new trial data, a regulatory decision, a corrected figure) are made in the article body and reflected in the dateModified field. Send corrections to hello@retatrutiderisk.com.
7. Medical disclaimer
Informational content, not medical advice. Retatrutide is an investigational compound, not approved by the FDA or the EMA.